Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Workday
WDAY
5
Lantheus
LNTH
US OptionsDetailed Quotes
MIRM250516P22500
- 0.00
- 0.000.00%
15min DelayClose Apr 30 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover0.00%IV48.22%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.87Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Mirum Pharmaceuticals Newsroom
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Cuts Target Price to $53
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $74
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $65
Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $55 to $74
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Mirum Pharmaceuticals Price Target Raised to $55.00/Share From $50.00 by Baird
Mirum Pharmaceuticals Analyst Ratings
Citi Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $68
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $65
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $74
Mirum Pharmaceuticals Analyst Ratings
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $74
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and AMN Healthcare Services (AMN)
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $63
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $60
Mirum Pharmaceuticals: Strong Financial Performance and Promising Pipeline Support Buy Rating
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $74
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call